Skip to main content

Greenberg Traurig Shareholders Roman Fayerberg and Cliff Merrell Presented at DeviceTalks: Minnesota

BOSTON — Oct. 1, 2015 — Roman Fayerberg and Cliff Merrell, shareholders at international law firm Greenberg Traurig LLP, were featured speakers at the 2015 DeviceTalks: Minnesota, Sept. 23, 2015, at the Science Museum of Minnesota.

On Wednesday, Sept, 23rd from 4 – 5:30 p.m., Fayerberg  and Merrell presented, "Putting on Your Legal Cap – Hot Legal Topics That Can Influence Your Medtech Company?” Specifically, the panel discussed:

  • What every medtech company needs to know about products liability litigation;
  • M&A trends from the perspective of both acquirer and seller; and
  • IP protection is key to a successful exit.

Fayerberg is a patent attorney and shareholder in Greenberg Traurig, LLP's Intellectual Property (IP) Group in Boston. He focuses on the development and management of strategic patent portfolios and counseling clients on patent issues, primarily in technologies related to life sciences. Fayerberg also advises clients in connection with intellectual property due diligence investigations for venture capital investment, mergers and acquisitions, and licensing opportunities. His patent practice builds on seven years of experience he gained as a research and development engineer at C.R. Bard and Boston Scientific Corporation.

Merrell is a shareholder in the firm’s Litigation Group in Atlanta. He focuses his practice on products liability litigation, with an emphasis on pharmaceutical and medical device litigation. As national counsel for many pharmaceutical and medical device manufacturers, Merrell has a wide range of experience managing products liability litigation in state court, federal court, and multidistrict litigation (MDL). He has litigated cases involving a wide range of branded and generic pharmaceutical products for pain relief, depression, weight loss, birth control, and menopause. He has also litigated cases involving a wide range of medical devices, including insulin pumps, surgical mesh, endotracheal tubes, neurostimulators, and implantable cardioverter-defibrillators (ICDs).